Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Fushilai Pharmaceutical Co., Ltd.

Request full access

Pharmaceutical ingredients for medicine and dietary supplements

ChinaFounded 2000

About Suzhou Fushilai Pharmaceutical Co., Ltd.

Suzhou Fushilai Pharmaceutical Co., Ltd. is a company that researches, develops, produces, and sells pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and raw materials for health products. Founded in November 2000, and formerly known as Changshu Fushilai Medicine & Chemical Co., Ltd., the company has grown significantly, expanding its facilities and moving to the Advanced Material Industrial Park in Changshu. The company went public on the Shenzhen Stock Exchange on March 29, 2022. Xiangyun Qian serves as the Chairman and General Manager.

The company's business model is centered on the manufacturing and global exportation of its core products, which include the lipoic acid series, carnosine series, and phosphatidylcholine series. These products are primarily supplied to the medicine, dietary supplement, and cosmetics industries. They are recognized for their benefits in anti-oxidation, delaying aging, and managing diabetic neuropathy. The company has established a global sales network, exporting to markets in Europe, America, and Southeast Asia, while also maintaining a significant market share in China. Fushilai operates under GMP (Good Manufacturing Practice) guidelines and has received certifications from the FDA.

Fushilai's main product lines feature a range of specialized ingredients. The lipoic acid series is used in medications for diabetic neuropathy complications. The L-carnosine series is applied in products aimed at delaying aging and in cosmetics. The phosphatidylcholine series is used in supplements for preventing conditions like neurasthenia and Alzheimer's disease. The company also produces other notable items such as imrecoxib API. In 2019, the company expanded its research and development capabilities by opening a new 8,000-square-meter R&D center.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2015
Outcome tier
Colt$25–100M revenue

Suzhou Fushilai Pharmaceutical Co., Ltd. in its local ecosystem

Live from Dealroom

The Suzhou Fushilai Pharmaceutical Co., Ltd. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Suzhou International Development Venture Capital Holding
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown
Web traffic by country
170 monthly visits
across markets
🇿🇦 South Africa58.8%
🇮🇹 Italy0%
Top 2 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Fushilai Pharmaceutical Co., Ltd. on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Fushilai Pharmaceutical Co., Ltd. on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.